CLDN18 and posterior cortical atrophy: Several studies have been conducted on the structural properties of claudin, and claudin-18.2 and claudin-4 have been demonstrated to be ideal therapeutic targets for PCa treatment, with the claudin -18.2- and claudin-4-targeted drugs in the clinical trial stages.